News Niek Savelkoul 10/6/26 Niek Savelkoul 10/6/26 Scope’s CRISPR Molecular Diagnostics CE marked for antifungal resistance Read More Niek Savelkoul 6/16/25 Niek Savelkoul 6/16/25 Scope Biosciences secures follow-on investment to scale up its CRISPR diagnostics platform Read More Niek Savelkoul 3/7/24 Niek Savelkoul 3/7/24 Scope Biosciences secures €2.5 Million EIC-Transition grant to revolutionize Point-of-Care diagnostics with the CRISPR-Cas based scopeDx platform Read More Niek Savelkoul 10/23/23 Niek Savelkoul 10/23/23 Scope Biosciences raises 500K investment from SHIFT and Oost NL Read More Niek Savelkoul 4/5/22 Niek Savelkoul 4/5/22 Laboratory at Campus Wageningen Read More Older Posts
Niek Savelkoul 10/6/26 Niek Savelkoul 10/6/26 Scope’s CRISPR Molecular Diagnostics CE marked for antifungal resistance Read More
Niek Savelkoul 6/16/25 Niek Savelkoul 6/16/25 Scope Biosciences secures follow-on investment to scale up its CRISPR diagnostics platform Read More
Niek Savelkoul 3/7/24 Niek Savelkoul 3/7/24 Scope Biosciences secures €2.5 Million EIC-Transition grant to revolutionize Point-of-Care diagnostics with the CRISPR-Cas based scopeDx platform Read More
Niek Savelkoul 10/23/23 Niek Savelkoul 10/23/23 Scope Biosciences raises 500K investment from SHIFT and Oost NL Read More
